PresentationSean LaamanHead of Healthcare Research & Equity Analyst Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, U.S. Head of SMid-Cap Biotech Equity Research here at the firm. Before we commence, for important disclosures, please see Morgan Stanley research disclosure website at www.morganstanley.com/research disclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Disc Medic ...

Question-and-Answer SessionMaybe just to commence proceedings, we've got a couple of macro questions here we've been asking all our companies. But the first one is with China's rise in biotech innovation, how are you thinking about Immunocore's competitive position here? And will this influence your R&D and business development strategy?Travis CoyCFO, Executive VP & Head of Corporate Development Yes. First of all, Sean, thank you for having us. We appreciate it. China, it's interesting. They've made great s ...

CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company for over two ...

PresentationMichael UlzEquity Analyst All right. Good afternoon, everyone. Thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here, and it's my pleasure to introduce the team from Arrowhead Pharmaceuticals. To my immediate left, Christopher Anzalone, CEO; and to my far left, James Hamilton, CMO and Head of R&D. Before we get started, I just need to read a quick disclosure. For important disclosures, please see the Morgan Stanley research discl ...

PresentationMichael UlzEquity Analyst All right. Good afternoon, everyone. Thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here, and it's my pleasure to introduce the team from Arrowhead Pharmaceuticals. To my immediate left, Christopher Anzalone, CEO; and to my far left, James Hamilton, CMO and Head of R&D. Before we get started, I just need to read a quick disclosure. For important disclosures, please see the Morgan Stanley research discl ...

PresentationSean LaamanHead of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. SMID Cap Biotech Equity Research here at the firm. Before we commence, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Relay The ...

PresentationSean LaamanHead of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. SMID Cap Biotech Equity Research here at the firm. Before we commence, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Relay The ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?When I last covered Travere Therapeutics, Inc. (NASDAQ: TVTX ) back in March, I gave its stock a Hold rating. I discussed the company securing an accelerated, followed by a full approval for its therapy Filspari (s ...

CytomX Therapeutics (NasdaqGS:CTMX) FY Conference September 10, 2025 01:05 PM ET Company ParticipantsRoss Cohen - Executive Director in Health Care Investment BankingSean A. McCarthy - CEORoss CohenHey, everybody. Really quickly on disclosures, for important disclosures, please see the Morgan Stanley Research disclosure website. If you have any questions, please reach out to a Morgan Stanley sales representative. Thank you all for joining. Welcome to the Morgan Stanley Health Care Conference. I'm delighted ...

Arcellx (NasdaqGS:ACLX) FY Conference September 10, 2025 01:05 PM ET Company ParticipantsRami Elghandour - CEOChristopher Heery - CMOMichelle Gilson - CFOConference Call ParticipantsJudah Frommer - AnalystJudah FrommerGood afternoon, everyone. Welcome to this session of the Morgan Stanley Global Healthcare Conference. I'm excited to welcome the Arcellx team to the stage. Let me just read a quick disclosure before we get into it. For important disclosures, please see the Morgan Stanley Research Disclosure we ...